Spots Global Cancer Trial Database for apatinib mesylate
Every month we try and update this database with for apatinib mesylate cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Camrelizumab Combined With Apatinib Mesylate for Head and Neck Squamous Cell Carcinoma | NCT04440917 | Head and Neck S... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects | NCT04457180 | Advanced Solid ... | Apatinib Mesyla... Repaglinide Bupropion | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Apatinib for Inoperable Advanced Chondrosarcoma | NCT04260113 | Efficacy Toxicity, Drug | Apatinib Mesyla... | - | Peking University People's Hospital | |
| An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | NCT05225844 | Gastrointestina... Immunotherapy Targeted Therap... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Harbin Medical University | |
| Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | NCT05019690 | Advanced Triple... | Apatinib Mesyla... Albumin-Bound P... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study | NCT03539172 | Soft Tissue and... Head and Neck C... Sarcoma | Apatinib Mesyla... | 10 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma | NCT04397770 | Melanoma | SHR1210 apatinib mesyla... Temozolomide In... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| Camrelizumab Combined With Apatinib Mesylate Tablets, Nab-paclitaxel and S-1 in the Treatment of Locally Advanced Gastric Cancer | NCT04195828 | Advanced Gastri... | Camrelizumab Apatinib Mesyla... nab-paclitaxel S1 | 18 Years - 75 Years | Fujian Medical University | |
| A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Transporter Pgp Substrate Digoxin in Advanced Solid Tumor Subjects | NCT04322552 | Advanced Solid ... | Apatinib Mesyla... Digoxin tablet | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab Plus Apatinib and Temozolomide as First Line Therapy in Advanced Acral Melanoma | NCT04397770 | Melanoma | SHR1210 apatinib mesyla... Temozolomide In... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| A Study of Apatinib in Recurrent/Metastatic Adenoid Cystic Carcinoma of the Head and Neck | NCT02775370 | Adenoid Cystic ... | Apatinib Mesyla... | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | NCT04850040 | Hepatocellular ... | Apatinib Mesyla... Camrelizumab Oxaliplatin | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | NCT06255392 | Breast Cancer | Fluzoparib Apatinib Mesyla... Capecitabine ta... Vinorelbine Tar... Eribulin mesyla... Gemcitabine Hyd... Paclitaxel-albu... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | NCT05095636 | Gastric Cancer Metastasis | Apatinib Mesyla... Camrelizumab | 18 Years - 75 Years | Fudan University | |
| The Safety and Efficacy of Thermal Ablation Combined With Apatinib and Carilimub for Advanced Liver Cancer | NCT04204577 | BCLC Stage B He... BCLC Stage C He... | Apatinib Mesyla... | 18 Years - 80 Years | Chinese PLA General Hospital | |
| Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer | NCT04590625 | Ovarian Cancer | Apatinib Mesyla... Abraxane Cis Platinum Carboplatin | 18 Years - 75 Years | Zhongshan Hospital Xiamen University | |
| Apatinib Combined With Chemotherapy in the Treatment of Soft Tissue Sarcoma | NCT04126811 | Soft Tissue Sar... | Apatinib Mesyla... Apatinib Mesyla... Pirarubicin, If... | 14 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study | NCT03539172 | Soft Tissue and... Head and Neck C... Sarcoma | Apatinib Mesyla... | 10 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study | NCT03539172 | Soft Tissue and... Head and Neck C... Sarcoma | Apatinib Mesyla... | 10 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | NCT02976896 | Esophageal Squa... | Apatinib Mesyla... | 18 Years - 75 Years | Sun Yat-sen University | |
| Camrelizumab Combined With Apatinib ,Carboplatin and Etoposide in Participants With ES-SCLC | NCT04683198 | Small-cell Lung... | camrelizumab Apatinib Mesyla... Carboplatin Etoposide | 18 Years - 70 Years | ChineseAMS | |
| Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | NCT05342389 | Metastatic Gast... Metastatic Gast... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer | NCT06255392 | Breast Cancer | Fluzoparib Apatinib Mesyla... Capecitabine ta... Vinorelbine Tar... Eribulin mesyla... Gemcitabine Hyd... Paclitaxel-albu... | 18 Years - 70 Years | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | |
| Apatinib for Inoperable Advanced Chondrosarcoma | NCT04260113 | Efficacy Toxicity, Drug | Apatinib Mesyla... | - | Peking University People's Hospital | |
| Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma | NCT04948125 | Advanced Gastri... | camrelizumab Apatinib Mesyla... | 18 Years - | Henan Cancer Hospital | |
| Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | NCT04521153 | Hepatocellular ... Immunotherapy Molecular Targe... | Camrelizumab Apatinib Mesyla... TACE treatment Radical surgery | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Camrelizumab Combined With Apatinib Mesylate and TACE in the Perioperative Treatment of Hepatocellular Carcinoma | NCT05613478 | Hepatocellular ... Immunotherapy Preoperative | Camrelizumab Apatinib Mesyla... Postoperative T... Radical surgery Preoperative TA... | 18 Years - | The First Affiliated Hospital with Nanjing Medical University | |
| Apatinib + Ifosfamide and Etoposide for Relapsed or Refractory Osteosarcoma | NCT04690231 | Effect of Drug Toxicity, Drug Secondary Resis... | Apatinib Mesyla... ifosfamide and ... | 3 Years - | Peking University People's Hospital | |
| Apatinib Plus Sintilimab in Advanced Gastric Cancer Refractory to at Least Two Previous Chemotherapy Regimens | NCT04089657 | Advanced Metast... | Apatinib Mesyla... Sintilimab | 20 Years - 75 Years | Fujian Cancer Hospital | |
| Apatinib Monotherapy Versus Apatinib Combined With Camrelizumab for Third-line Treatment of Metastatic Gastric Cancer | NCT05095636 | Gastric Cancer Metastasis | Apatinib Mesyla... Camrelizumab | 18 Years - 75 Years | Fudan University | |
| PD-1 Antibody SHR-1210 Combined With Apatinib of First-line Treatment of Advanced Acral Melanoma | NCT03955354 | Melanoma | SHR1210 apatinib mesyla... | 18 Years - 75 Years | Peking University Cancer Hospital & Institute | |
| PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | NCT04174339 | Advanced Gastri... | Camrelizumab Apatinib Mesyla... POF | 18 Years - 70 Years | Fujian Cancer Hospital | |
| Preoperative IMRT With Concurrent Apatinib for Localised Extremity or Trunk Sarcoma | NCT05235100 | Sarcoma,Soft Ti... Extremity Trunk Intensity-modul... Targetd Therapy Major Wound Com... | Apatinib Mesyla... | 18 Years - | ChineseAMS | |
| A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment | NCT02711969 | Gastric Cancer | Apatinib mesyla... | 19 Years - | Bukwang Pharmaceutical | |
| Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment | NCT02976896 | Esophageal Squa... | Apatinib Mesyla... | 18 Years - 75 Years | Sun Yat-sen University | |
| Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | NCT05751733 | Gastrointestina... | Apatinib Mesyla... Sunitinib, Imat... | 18 Years - | Xiangya Hospital of Central South University | |
| Albumin-Bound Paclitaxel Combined With Antiangiogenic Agents in First-line Treatment of Relapsed or Metastatic TNBC | NCT05192798 | Triple-negative... | Albumin-Bound P... Apatinib Mesyla... Bevacizumab | 18 Years - 80 Years | First Affiliated Hospital Bengbu Medical College | |
| Apatinib Mesylate Versus Standard Second-line TKI in the Treatment of Advanced GIST | NCT05751733 | Gastrointestina... | Apatinib Mesyla... Sunitinib, Imat... | 18 Years - | Xiangya Hospital of Central South University | |
| A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | NCT04850040 | Hepatocellular ... | Apatinib Mesyla... Camrelizumab Oxaliplatin | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| Comparison of MAPI+Camrelizumab Versus API+Apatinib Versus MAPI in Patients With a Poor Response to Preoperative Chemotherapy for Newly Diagnosed High-grade Osteosarcoma | NCT04351308 | Osteosarcoma Survival Chemotherapy Ef... Toxicity, Drug | MAPI chemothera... Apatinib Mesyla... Camrelizumab | 12 Years - | Peking University People's Hospital | |
| Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | NCT05342389 | Metastatic Gast... Metastatic Gast... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Sixth Affiliated Hospital, Sun Yat-sen University | |
| Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | NCT05156970 | Recurrent Head ... Metastatic Head... | Camrelizumab Cisplatin Docetaxel Apatinib Mesyla... Carboplatin | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| An Exploratory Trail of Camrelizumab Plus Apatinib Mesylate for Advanced Gastrointestinal | NCT05225844 | Gastrointestina... Immunotherapy Targeted Therap... | Camrelizumab Apatinib Mesyla... | 18 Years - 75 Years | Harbin Medical University | |
| A Neoadjuvant Hepatocellular Carcinoma Study of Camrelizumab in Combination With Apatinib and Oxaliplatin | NCT04850040 | Hepatocellular ... | Apatinib Mesyla... Camrelizumab Oxaliplatin | 18 Years - 70 Years | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | |
| A Study of Apatinib Mesylate (YN968D1) 1,000mg in Gastric Cancer Patient Failed to Standard Treatment | NCT02711969 | Gastric Cancer | Apatinib mesyla... | 19 Years - | Bukwang Pharmaceutical | |
| Camrelizumab Combined With Apatinib Mesylate Tablets and Nab-paclitaxel in the Second-line Treatment of Advanced Gastric Cancer | NCT04572542 | Locally Advance... | Camrelizumab Apatinib Mesyla... nab-paclitaxel | 18 Years - 75 Years | The First Affiliated Hospital of Xiamen University | |
| Phase 2 Trial of Apatinib Mesylate in Locally Advanced/Metastatic Differentiated Thyroid Carcinoma | NCT03167385 | Differentiated ... | Apatinib Mesyla... | 18 Years - 75 Years | Tianjin Medical University Cancer Institute and Hospital | |
| Study to Evaluate the Efficacy and Safety of Camrelizumab and Apatinib in Patients With GC/GEJC | NCT04342910 | Gastric Cancer | camrelizumab Apatinib Mesyla... Paclitaxel Irinotecan | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Radiotherapy Concurrent With Apatinib in Advanced Soft Tissue and Bone Sarcomas of Head and Neck--RASS Study | NCT03539172 | Soft Tissue and... Head and Neck C... Sarcoma | Apatinib Mesyla... | 10 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Camrelizumab Combined With Apatinib for Advanced Gastric or Esophagogastric Adenocarcinoma | NCT04948125 | Advanced Gastri... | camrelizumab Apatinib Mesyla... | 18 Years - | Henan Cancer Hospital | |
| PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric Cancer | NCT04174339 | Advanced Gastri... | Camrelizumab Apatinib Mesyla... POF | 18 Years - 70 Years | Fujian Cancer Hospital | |
| A Pharmacokinetic Interaction Study Between Apatinib Mesylate and Repaglinide or Bupropion in Advanced Solid Tumor Subjects | NCT04457180 | Advanced Solid ... | Apatinib Mesyla... Repaglinide Bupropion | 18 Years - 70 Years | Jiangsu HengRui Medicine Co., Ltd. | |
| Camrelizumab Combined With Apatinib 、XELOX 、RFA in the Treatment of Liver Metastases of Colorectal Cancer | NCT04202978 | Hepatic Metasta... | Camrelizumab Apatinib Mesyla... Capecitabine Oxaliplatin radiofrequency ... | 18 Years - 75 Years | Zhongshan Hospital Xiamen University | |
| Apatinib Combined With Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer | NCT05019690 | Advanced Triple... | Apatinib Mesyla... Albumin-Bound P... | 18 Years - 75 Years | Fujian Cancer Hospital | |
| Camrelizumab in Combination With Chemotherapy or Apatinib Mesylate as First-Line Treatment for R/M HNSCC | NCT05156970 | Recurrent Head ... Metastatic Head... | Camrelizumab Cisplatin Docetaxel Apatinib Mesyla... Carboplatin | 18 Years - 75 Years | Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University | |
| Tislelizumab Combined With Apatinib and Oxaliplatin Plus S1 as Neoadjuvant Therapy for Borrmann IV、Large Borrmann III Type and Bulky N Positive Advanced Gastric Cancer | NCT05223088 | Immunotherapy Gastrict Cancer | Tislelizumab Apatinib Mesyla... oxaliplatin Tegafur | 18 Years - 75 Years | Fujian Cancer Hospital | |
| SHR-1210 Combined With Apatinib Mesylate in the Perioperative Therapy for Hepatocellular Carcinoma | NCT04930315 | Hepatocellular ... | Apatinib Mesyla... Camrelizumab | 18 Years - 75 Years | Zhejiang University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
